Boston Partners Grows Stake in Tenet Healthcare Corporation $THC

Boston Partners increased its stake in shares of Tenet Healthcare Corporation (NYSE:THC) by 15.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,642,136 shares of the company’s stock after buying an additional 494,581 shares during the quarter. Boston Partners’ holdings in Tenet Healthcare were worth $723,804,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Triumph Capital Management purchased a new stake in shares of Tenet Healthcare during the third quarter valued at $25,000. Activest Wealth Management purchased a new stake in shares of Tenet Healthcare during the fourth quarter valued at $26,000. Elyxium Wealth LLC purchased a new stake in shares of Tenet Healthcare during the fourth quarter valued at $29,000. Canada Pension Plan Investment Board purchased a new stake in shares of Tenet Healthcare during the second quarter valued at $35,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Tenet Healthcare by 146.2% during the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after buying an additional 114 shares during the last quarter. 95.44% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Tenet Healthcare

In other Tenet Healthcare news, Director Nadja West sold 3,000 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total value of $532,050.00. Following the completion of the sale, the director owned 24,805 shares in the company, valued at approximately $4,399,166.75. This represents a 10.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Robert Kerrey sold 5,638 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the sale, the director owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.97% of the stock is currently owned by corporate insiders.

Tenet Healthcare Stock Up 0.9%

THC opened at $174.67 on Friday. Tenet Healthcare Corporation has a twelve month low of $146.60 and a twelve month high of $247.21. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. The company has a 50-day moving average price of $183.94 and a 200 day moving average price of $199.94. The company has a market cap of $15.05 billion, a PE ratio of 9.08, a price-to-earnings-growth ratio of 1.43 and a beta of 1.28.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, topping the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The firm had revenue of $5.37 billion during the quarter, compared to the consensus estimate of $5.39 billion. During the same quarter in the prior year, the firm earned $4.36 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Sell-side analysts expect that Tenet Healthcare Corporation will post 17.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wells Fargo & Company decreased their target price on shares of Tenet Healthcare from $265.00 to $213.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Wall Street Zen downgraded shares of Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 11th. Robert W. Baird decreased their price objective on shares of Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. Guggenheim decreased their price objective on shares of Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Finally, Leerink Partners upped their price objective on shares of Tenet Healthcare from $255.00 to $264.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. Eighteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $244.16.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.